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ABSTRACT
Background. Despite the growing interest in haemodiaﬁltra-
tion (HDF), there is no information on the costs and cost–
utility of this dialysis modality yet. It was therefore our objec-
tive to study the cost–utility of HDF versus haemodialysis
(HD).
Methods. A cost–utility analysis was performed using a
Markov model. It included data from the Convective Trans-
port Study (CONTRAST), a randomized controlled trial that
compared online HDF with low-ﬂux HD. Costs were esti-
mated using a societal perspective. Probabilistic sensitivity
analyses were performed to study uncertainty.
Results. Total annual costs for HDF and HD were
€88 622 ± 19 272 and €86 086 ± 15 945, respectively (in
2009 euros). When modelled over a 5-year period, the in-
cremental cost per quality-adjusted life year (QALY) of
HDF versus HD was €287 679. Sensitivity analyses re-
vealed that this amount will not fall below €140 000, even
under the most favourable assumptions like a high-con-
vection volume (>20.3 L).
Conclusions. Based on accepted societal willingness-to-pay
thresholds, HDF cannot be considered a cost-effective treat-
ment for patients with end-stage renal disease at present. Ap-
parently, minor additional costs of HDF are not
counterbalanced by a relevant QALY gain.
© The Author 2013. Published by Oxford University Press on
behalf of ERA-EDTA. All rights reserved.
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In-centre haemodialysis (HD) is one of the most expensive
chronic health care interventions. Indeed, the costs per
quality-adjusted life year (QALY, a hypothetical year in
optimal health) of HD have been recognized as a kind of
benchmark for society’s willingness to pay for medical tech-
nologies [1]. Both survival and quality of life are strongly im-
paired in patients with end-stage renal disease (ESRD) [2, 3].
Their quality of life is, for instance, lower than in patients with
respiratory or coronary disease, arthritis or metastatic colorec-
tal cancer [4].
Dialysis therapies like peritoneal dialysis and home (noc-
turnal) HD are cost-effective compared with in-centre HD [5–
9]. A kidney transplantation is the most cost-effective treat-
ment for patients with ESRD, but not all patients are able to
undergo transplantation, and treatment availability is low due
to a shortage in donor kidneys [9]. Furthermore, not all
patients are able to undergo transplantation [9]. Online hae-
modiaﬁltration (HDF) might be a cost-effective alternative to
HD [10]. HDF combines diffusion with convection to enhance
the clearance of middle molecules. Recently, however, large
randomized controlled trials revealed that there is no signiﬁ-
cant beneﬁt in terms of survival associated with HDF [11, 12].
Possibly, a positive effect in patient reported outcomes such as
quality of life could tip the balance favourably. Conversely, the
costs of HDF are also unclear. Accordingly, there is a strong
need for an economical evaluation. We therefore aimed to
assess the cost-effectiveness of HDF when compared with HD.
MATERIALS AND METHODS
Clinical trial
The present study was conducted in parallel with the Con-
vective Transport Study (CONTRAST) [11, 13]. CONTRAST
is a randomized controlled trial (NCT00205556) that com-
pared online post-dilution HDF with low-ﬂux HD on all-
cause mortality. Between June 2004 and December 2009, it in-
cluded 714 patients aged 18 years or above with ESRD under-
going chronic intermittent HD in 29 dialysis centres located in
the Netherlands (n = 26), Canada (n = 2) and Norway (n = 1).
Follow-up was uniformly stopped in December 2010. CON-
TRAST was approximately halfway completed when the cost–
utility analysis started. This means that prospective data on
both costs and quality of life were available in 409 of the 714
patients. Written informed consent was obtained from all
patients prior to randomization. The study was conducted in
accordance with the Declaration of Helsinki and Good Clinical
Practice Guidelines and was approved by central and local
medical ethics review boards. Detailed information on study
design and conduct can be found elsewhere [11, 13].
Cost–utility analysis
Cost analysis. The cost analysis was performed from a
societal perspective. Costs were calculated per 3 months in
2009 euros [1 euro = 1.43 US dollars (2009 exchange rate)]. If
necessary, cost estimates were indexed to 2009 with the Dutch
consumer price indices (http://statline.cbs.nl).
To arrive at our ﬁnal cost estimates, we combined bottom-
up measurements (i.e. registration of the use of resources at
the level of participating patients) with top-down estimates for
those cost categories that were thought to be similar for all
patients, e.g. costs of disposables used during dialysis. The cost
analysis included direct healthcare costs as well as direct and
indirect non-healthcare costs. Direct healthcare costs com-
prised dialysis and other medical staff, material (water installa-
tion, dialysis machines and disposables), vascular access,
routine diagnostics of patients and dialysis water quality,
meals during dialysis, hospitalization, medication and over-
head. Direct non-healthcare costs comprised travel expenses
and indirect non-healthcare costs included productivity losses.
Productivity losses cover productivity loss with and without
the absence of paid work and substitution of unpaid, domestic
work either by family or by home care. Dialysis staff involve-
ment in relation to the number of patients was estimated with
a cross-sectional analysis in 24 Dutch dialysis centres. A refer-
ence price per full-time equivalent for different job levels was
obtained from the Dutch guideline for costing research [14].
Reference prices were also available for the visits to the outpa-
tient department, general practitioner, paramedic, psychologist
and complementary medicine. The number of patient visits to
these healthcare workers was assessed prospectively with a 3-
monthly patient questionnaire. Material costs were provided
by a categorical (Dianet) and two university hospitals (Univer-
sity Medical Centre Utrecht and VU Medical Centre). The
costs of vascular access were calculated as a weighted average
of the costs for an arteriovenous ﬁstula, graft or catheter using
the data fromWijnen et al. [15] and Manns et al. [16]. The fre-
quency of microbiological and endotoxin testing of (ultra)pure
water for dialysis is based on the guideline of the Dutch Ne-
phrology Federation [17]. Prices were provided by the
pharmacology department of the VU Medical Centre. The fre-
quency of the laboratory diagnostics is based on the guideline
of the Dutch Nephrology Federation [18]; the frequency of
other diagnostic procedures (chest X-rays and electrocardio-
grams) on a protocol from the University Medical Centre
Utrecht. Prices for these diagnostic procedures were obtained
from the Dutch Diagnostic Compass issued by the Health
Care Insurance Board [19]. The cost for meals during dialysis
were estimated to be 200 euros per 3 months, based on 5 euros
per meal and 3 dialysis sessions per week. The price of hospi-
talization is based on reference prices from the Dutch guide-
line for costing research, where 1 day of hospitalization for a
patient in the Netherlands was calculated to cost €457 on
average [14]. Hospitalization and medication use were
measured in CONTRAST patients and analysed per age cat-
egory. Medication use included anaemia drugs, anticoagulants
and antiplatelets, antihypertensive drugs, cinacalcet, phos-
phate binders, resonium, statins and vitamin D3. Prices were
based on the Dutch Pharmacotherapeutical Compass from the
Health Care Insurance Board (http://www.fk.cvz.nl/). The
Pharmacotherapeutical Compass delivers prices per unit or
per time period of standard use. As recommended by the
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calculated as a percentage (35.5%) of direct healthcare costs
that did not yet include overhead [14]. Travel expenses were
based on 3-weekly visits to a dialysis centre, using the average
distance to a Dutch hospital and reference prices per km of
taxi use as available from the costing guideline [14]. Pro-
ductivity loss was assessed with a modiﬁed version of the
Short-Form Health and Labour Questionnaire and valued
using the friction cost approach [20, 21].
Quality-adjusted life years. QALY’s were calculated by mul-
tiplying survival with utility. Survival data were provided by
the main trial as described elsewhere [11]. To obtain QALY’s,
survival was adjusted for quality of life with an adjustment
factor called ‘utility’. This utility weight has a score from 0 to 1
(i.e. the worst to best imaginable state of health). Utility was
assessed every 3 months with the Euroqol 5D (EQ-5D). This
questionnaire offers the transfer of the quality of life scores of
patients to societal utilities for patients’ health states using the
Dutch data [22, 23]. The validated EQ-5D is one of the most
widely used instruments to measure health utility and is pre-
ferred by National Institute for Health and Clinical Excellence
[24, 25]. Missing EQ-5D is imputed by mean values as only
7% of QOL data were missing in our trial.
Statistical analysis
The cost–utility of HDF versus HD was analysed using a
Markov model. Cost–utility was determined for three age cat-
egories: 18–44 years, 45–64 and 65 and older. The model in-
cluded two health states, ‘ESRD’ and ‘Death’, with treatment-
dependent and -independent parameters for costs, utilities
and transition probabilities. Probabilistic sensitivity analyses
were performed to include parameter uncertainty. A total of
1000 bootstrap replicates were obtained using Microsoft Ofﬁce
Excel 2003. The cycle duration was 3 months as follow-up
data were available from the CONTRAST trial for these inter-
vals. The time horizon of the model was 5 years, and a sensi-
tivity analysis was performed with a time horizon up to 10
years. In compliance with Dutch guidelines, a discount rate of
4% was applied for costs and 1.5% for outcome [14]. A second
sensitivity analysis was performed to evaluate a uniform dis-
count rate, namely 3% for both costs and outcome. As CON-
TRAST data suggested that HDF had a beneﬁcial effect on
survival if a high convection volume (>20.3 L) was provided
[11], a third sensitivity analysis was performed using utility
and transition probability measures of HDF patients with the
high convection volume. A ﬁnal sensitivity analysis was per-
formed to explore the inﬂuence of excluding standard dialysis
costs in life years gained. As pointed out by Grima et al. [26],
life-extending interventions in dialysis may never be cost-ef-
fective as a result of high background costs of dialysis itself,
often already exceeding threshold values for cost-effectiveness.
In this sensitivity analysis, costs due to life years gained by
HDF were excluded by using the survival of HD patients for
the HDF population, implying that health beneﬁts of HDF
were solely related to the quality of life differences between
therapies in this sensitivity analysis.
To evaluate whether HDF and HD patients who partici-
pated in the cost–utility analysis were comparable at baseline,
the independent t-test, Mann–Whitney test or Fisher’s exact
test was applied if appropriate. These analyses were performed
with SPSS 18 (SPSS Inc., Chicago, IL, USA). Results were con-




Patients participating in the cost–utility data collection
were equal at baseline, except for a small but signiﬁcant differ-
ence in spKt/V urea (HDF: 1.45 ± 0.25; HD: 1.39 ± 0.20;
P = 0.01).
Cost analysis
Table 1 depicts the costs of HDF and HD per 3 months in
2009 euros. A detailed description of the different cost units
can be found in Supplementary material Tables S1–S12. Total
annual costs for HDF and HD were €88 622 ± 19 272 and €86
086 ± 15 945, respectively, based on measured costs per
quarter. Overall, the higher costs for HDF when compared
with HD could mainly be attributed to higher expenses for dis-
posables and a more frequent control of water purity.
Utility
Table 2 shows the utility of ESRD per age category while on
HDF or HD, as well as the transition probabilities from ESRD
to death per 3 months. Overall utility in patients on HDF was
slightly higher when compared with HD, and mortality was
slightly lower.
Cost–utility ratios
Table 3 shows the cost–utility of HDF and HD for a patient
aged 45–65 years, when modelled over a period of 5 years.
Over this period, the incremental costs per QALY of HDF
versus HD were €287 679, and the incremental costs per life
year gained were €206 057. The uncertainty associated with
these ﬁgures is depicted in Figure 1: the cost-effectiveness
plane of HDF versus HD. Figure 2 shows the cost-effectiveness
acceptability curve (CEAC). It displays the probability of cost-
effectiveness of HDF versus HD for different ceiling ratios, i.e.
different thresholds society would be willing to pay for an
additional QALY. Results show that, only at ceiling ratios over
€300 000 per QALY, the probability that HDF is more cost-ef-
fective compared with HD surpasses 50%. Based on the small
difference in incremental effect, HDF would be cost-effective if
its incremental annual cost was lower than €294 or €960,
respectively, based on the usual or upper limit of Dutch so-
ciety’s willingness to pay (i.e. €24 500 or €80 000 per QALY)
[27].
In patients younger than 45, the 5-year incremental costs of
HDF versus HD were €21 637 (95% conﬁdence interval: −17
652–72 458) for 0.12 (−0.52–0.81) additional QALYs. In this
group, only at ceiling ratios of €220 000 and higher, HDF had
a higher probability than HD to be cost-effective. In patients
aged 65 and older, the incremental costs of HDF versus HD
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additional QALYs. In these patients, the probability of HDF
being cost-effective compared with HD is unlikely, even at
ceiling ratios as high as €300 000.
Sensitivity analyses. For patients aged 45–65, three sensi-
tivity analyses were performed. First, if a time horizon of 10
instead of 5 years was applied, the incremental cost for HDF





Other medicala 347 ± 297 353 ± 312
Material
Water installation 107 107
Dialysis machine 231 231
Disposables 2552 1895
Vascular accessb 362 362
Routine diagnostics
Puriﬁed water for dialysis 77 24
Dialysis patientc 284 284
Meals 200 200
Hospitalization
Overall 1566 ± 4332 1533 ± 3536
Age <45 1181 ± 6416 481 ± 1806
Age 45–64 1560 ± 4702 1552 ± 3706
Age ≥65 1648 ± 3538 1721 ± 3632
Medication
Overall 3681 ± 1428 3696 ± 1462
Age <45 3871 ± 1715 3731 ± 1041
Age 45–64 3847 ± 1478 4017 ± 1732
Age ≥65 3544 ± 1322 3446 ± 1259
Overheadd 4059 3807
Direct non-healthcare costs
Travel expenses 1365 1365
Indirect non-healthcare costs
Productivity losse 225 ± 1140 270 ± 1064
Total
Per 3 months 22 155 ± 4818 21 521 ± 3986
Per year 88 622 ± 19 272 86 086 ± 15 945
Costs are depicted as mean ± standard deviation if available. Most distributions were left-skewed. 1 euro = 1.43 US dollars (2009 exchange
rate).
aVisits to the medical specialist, general practitioner, paramedic, psychologist and alternative healers.
bBased on a weighted average of the costs for an arteriovenous ﬁstula, graft or catheter[15, 16].
cLaboratory analyses, electrocardiogram and chest X-ray.
dCalculated as a percentage (35.5%) of direct healthcare costs that did not yet include overhead.
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versus HD was €25 443 (15 208–35 377) with 0.14 (−0.08–
0.35) additional QALYs. The probability that HDF would be
cost-effective compared with HD surpassed 50% at ceiling
ratios above €190 000 per QALY.
Secondly, a uniform discount rate of 3% for both costs and
outcome, resulted in an incremental cost of €16 928 (2866–
30 425) while on HDF for 0.07 (−0.09–0.21) additional
QALYs. Even with ceiling ratios of €250 000 per QALY, HDF
did not become more cost-effective than HD.
Thirdly, if only HDF utilities and transition probabilities
for patients with the high convection volume (>20.3 L) were
applied [overall utility: 0.75 ± 0.02 (± standard error of the
mean, SE) and overall mortality probability: 0.0217 ± 0.0039
(±SE)], the additional costs of HDF resulted in 0.29 ± 0.16
(−0.02–0.61) additional QALYs. In this scenario analysis, at a
ceiling ratio starting from €140 000 per QALY, HDF is ex-
pected to be more cost-effective than HD.
Fourthly, if costs due to life years gained by HDF were ex-
cluded by using the survival of HD patients for the HDF popu-
lation, the incremental cost for HDF versus HD was €10 349
(−€17 792–37 536) for 0.01 (−0.26–0.27) additional QALYs.
The probability that HDF would be cost-effective compared
with HD did not surpass 50%, even at ceiling ratios of €250
000 per QALY.
DISCUSSION
This study showed that, even though the additional costs of
HDF seem minor when compared with HD, they are not out-
weighed by the limited QALY gain. Elaborate sensitivity ana-
lyses revealed that society should be willing to pay €140 000–
300 000 per additional QALY for HDF to become cost-effec-
tive compared with HD. These ﬁgures by far exceed currently
accepted thresholds. In the Netherlands, the average willing-
ness to pay is €24 500 per QALY with a suggested upper limit
of €80 000 [27]. In the UK, this threshold is £20 000–30 000
per QALY and in the USA, $50 000–$100 000 [28]. Thus,
HDF exceeds society’s willingness to pay for health, even more
so because the cost-effectiveness is assessed by comparison
with (i.e. investments on the top of) a treatment that already is
considered to be of borderline cost-effectiveness [1].
The relatively small additional costs of HDF could mainly
be attributed to higher expenses for disposables and a more
frequent control of dialysis water purity. In our study, all dialy-
sis centres already used ultrapure dialysis ﬂuids for both HDF
and HD as recommended, so no additional investments in
water puriﬁcation were required to commence with online
HDF. The price of disposables is often open for negotiations
with suppliers/manufacturers. Bearing this in mind, HDF
could become within currently accepted standards for cost-ef-
fectiveness when its incremental costs compared with HD
would be below €294–960. A relatively frequent control of ul-
trapure water is prescribed in the Netherlands [17]. A less
strict regime as recommended by the International Organiz-
ation for Standardization (ISO) [29] does, however, not lower
HDF costs signiﬁcantly: €66 per 3 months instead of €77 for
the control of puriﬁed water. Hence, this would hardly inﬂu-
ence the unfavourable incremental cost-effectiveness of HDF
compared with HD.
To our knowledge, this study is the ﬁrst to evaluate the
cost–utility of HDF. We furthermore provide an update on the
current costs of HD from a societal perspective. The last de-
tailed cost analysis of HD in the Netherlands was published in
1997 by de Wit et al. [6]. Converted to 2009 euros, their esti-
mate of prevalent HD cost per year was €85 031, which is com-
parable with our results (€86 992). This indicates that there
Table 3: HDF and HD: modelled costs, QALYs and survival over 5 years
Haemodiaﬁltration Haemodialysis Haemodiaﬁltration versus haemodialysis
Costs (€) 283 931 (264 500–303 187) 267 543 (248 294–286 157) 16 388 (−10 242–43 010)
QALYs 2.40 (2.22–2.59) 2.34 (2.17–2.53) 0.06 (−0.19–0.32)
Life years 3.43 (3.21–3.65) 3.35 (3.12–3.56) 0.08 (−0.22–0.39)
Depicted are means with 95% conﬁdence intervals based on a patient aged 45–65.
The third column shows the incremental cost and effectiveness of HDF versus HD.
QALY: quality-adjusted life year.
Table 2: Utility and transition probability for
death on HDF and HD
Haemodiaﬁltration Haemodialysis
Utility
Overall 0.74 ± 0.01 0.73 ± 0.02
Age <45 0.81 ± 0.04 0.77 ± 0.06
Age 45–64 0.76 ± 0.02 0.73 ± 0.02
Age ≥65 0.72 ± 0.02 0.72 ± 0.02
Transition probability for death per 3 months
Overall 0.0297 ± 0.0026 0.0315 ± 0.0027
Age <45 0.0044 ± 0.0025 0.0019 ± 0.0019
Age 45–64 0.0192 ± 0.0035 0.0221 ± 0.0035
Age ≥65 0.0456 ± 0.0047 0.0479 ± 0.0050
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were no relevant changes in HD costs between 1997 and 2009.
To provide an international reference with regard to the recent
cost estimates on HD, Table 4 presents the cost data of ﬁve
recent international cost analyses. Table 5 furthermore pro-
vides a reference with regard to international cost–utility esti-
mates of HD. Unfortunately, a strict comparison is hampered
due to different viewpoints and cost allocation methods.
Our model has limitations. First, due to selection criteria
and repeated measurements, patients in a randomized clinical
trial might be healthier and subjected to a higher level of care
when compared with patients in general. Whereas this might
inﬂuence the generalizability of data, it is unlikely to inﬂuence
the cost–utility of HDF versus HD. Secondly, as explained in
the Materials and Methods section, the prospective analysis of
costs and utility started when the main trial, CONTRAST, was
approximately halfway. Participating HDF and HD patients
may therefore not be viewed as a random sample as they
already survived up until that time. However, there was only a
small difference between HDF and HD participants, namely in
Kt/V. As the HEMO study did not ﬁnd a clear effect of Kt/V
on quality of life or survival [30, 31], it can be excluded as a
potential confounder. The comparison therefore remains
valid. Finally, patients and health care professionals could not
be blinded for the allocation of treatment, which might induce
a placebo effect. If any, this might have a positive effect on
utility measures in HDF patients.
In conclusion, HDF is not a more cost-effective option to
treat ESRD patients than HD. Although the additional costs of
F IGURE 1 : Cost-effectiveness plane of HDF versus HD. This ﬁgure shows the cost–utility of HDF versus HD as modelled with 1000 bootstrap
replicates for 1000 patients aged 45–65 over a 5 year time period. Each dot represents the average for 1000 patients. Whereas sometimes HDF is
both cheaper and less effective than HD (the dots in the left lower quadrant), most often HDF is more expensive and more effective (the dots in
the right upper quadrant). HDF: haemodiaﬁltration; HD: haemodialysis; QALY: quality-adjusted life year.
F IGURE 2 : CEAC of HDF versus HD. This ﬁgure shows the probability that HDF or HD is the most cost-effective treatment for different
ceiling ratios in patients aged 45–64. A ceiling ratio is the price society that is willing to pay for a QALY. Overall HDF is more costly and more ef-
fective than HD, which means that if the ceiling ratio increases, the probability that HDF becomes the most effective treatment increases. HDF:
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Table 4: The cost of HD in the recent international literature
















Spain 2010 €37 968 €37 491b €43 709
Haller et al.
[9]
Healthcare? Austria 2008 €40 600a €41 087b €40 773








Society Australia 2008 $AU
202 124c
€100 893 €116 947
$AU
215 354d
€107 496 €124 601
USRDS: United States Renal Data System.
aCosts for HD beyond 25 months.
bOnly adjusted for difference in the pricing year using the consumer price index (http://statline.cbs.nl/statweb/).
cPatients with a late start of dialysis: estimated glomerular ﬁltration rate of 5–7 mL/min/1.73 m2.
dPatients with an early start of dialysis: estimated glomerular ﬁltration rate of 10–14 mL/min/1.73 m2.
Table 5: The cost–utility of HD in international literature









McFarlane et al. [7] Healthcare Canada 2000–01 $CAN
125 845
€105 183a €109 789a





Healthcare UK 2001–02 £65 817b €115 566c €105 988c
Lee et al. [1] Healthcare USA 1996–2003 $129 090 €118 484d €131 367d
Harris et al. [35] Society Australia 2008 $AU
405 224e
€202 272 €234 458
$AU
453 665f
€226 452 €262 485
QALY: quality-adjusted life year.
aWhen the year 2001 is regarded as the price reference year.
bBased on £22 246 per year for 1.69 QALYs during 5 years of follow-up.
cWhen the year 2002 is regarded as the price reference year.
dWhen the year 2003 is regarded as the price reference year.
ePatients with a late start of dialysis: estimated glomerular ﬁltration rate of 5–7 mL/min/1.73 m2. Based on $AU 202 124 per year for 2.07
QALYs during 4.15 years of follow-up.
fPatients with an early start of dialysis: estimated glomerular ﬁltration rate of 10–14 mL/min/1.73 m2. Based on $AU 215 354 per year for
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HDF were limited, they were not compensated for by its mar-
ginal positive effect on utility. HDF could become cost-effec-
tive when its incremental costs, compared with HD, will be
lowered to a maximum of €960.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.
oxfordjournals.org.
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